Source:http://linkedlifedata.com/resource/pubmed/id/12409642
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2002-10-31
|
pubmed:abstractText |
Testing for alterations in HER-2/neu in breast cancer has become increasingly popular in recent years, particularly with the recent development of a humanized antiHER-2/neu monoclonal antibody, trastuzumab, which is currently being employed in conjunction with cytotoxic chemotherapy to treat metastatic breast cancer in patients whose tumors exhibit this HER-2/neu alteration. Controversy exists not only on the optimal method of laboratory testing for this HER-2/neu alteration (i.e., fluorescence in situ hybridization (FISH) versus immunohistochemistry (IHC) versus others), but also on the type of reagents used for a given method. A plethora of published studies on tissue-based HER-2/neu testing has recently appeared in many peer-reviewed journals; many have concluded that IHC could be used as a first-line screening test, with the recommendation of FISH to confirm indeterminate results. In contrast to these studies, a recent study by Pauletti et al. showed that HER-2/neu testing by IHC does not predict clinical outcome as accurately as does FISH. This commentary discusses the findings of this study, within a broader review of critical issues relating to HER-2/neu testing in breast cancer.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1072-4109
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
9
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
338-44
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:12409642-Antibodies, Monoclonal,
pubmed-meshheading:12409642-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:12409642-Breast Neoplasms,
pubmed-meshheading:12409642-Female,
pubmed-meshheading:12409642-Humans,
pubmed-meshheading:12409642-Immunoenzyme Techniques,
pubmed-meshheading:12409642-In Situ Hybridization, Fluorescence,
pubmed-meshheading:12409642-Mass Screening,
pubmed-meshheading:12409642-Pilot Projects,
pubmed-meshheading:12409642-Prognosis,
pubmed-meshheading:12409642-Receptor, erbB-2,
pubmed-meshheading:12409642-Reproducibility of Results,
pubmed-meshheading:12409642-Survival Rate
|
pubmed:year |
2002
|
pubmed:articleTitle |
Testing for HER-2/neu in breast cancer: is fluorescence in situ hybridization superior in predicting outcome?
|
pubmed:affiliation |
PhenoPath Laboratories, 551 North 34th Street, Suite 100, Seattle, WA 98103, USA.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Comment,
Review
|